Seres Therapeutics, Inc. (MCRB) is a publicly traded Healthcare sector company. As of May 21, 2026, MCRB trades at $7.79 with a market cap of $73.50M and a P/E ratio of -1.45. MCRB moved +1.88% today. Year to date, MCRB is -49.57%; over the trailing twelve months it is -7.04%. Its 52-week range spans $6.53 to $29.98. Analyst consensus is buy with an average price target of $22.00. Rallies surfaces MCRB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Seres Posts $19.9M Q1 Loss, Eyes SER-155 Trial Readout and SER-603 Progress: Seres reported a Q1 net loss of $19.9 million on $358,000 revenue, versus a $32.7 million profit in Q1 2025 after a $50 million Nestlé payment. The company expects data from its 15-patient SER-155 trial in immune-related enterocolitis and is advancing IND studies on its SER-603 IBD candidate.
| Metric | Value |
|---|---|
| Price | $7.79 |
| Market Cap | $73.50M |
| P/E Ratio | -1.45 |
| EPS | $-5.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $29.98 |
| 52-Week Low | $6.53 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.15M |
| Net Income | $-46.90M |
| Gross Margin | 0.00% |
1 analysts cover MCRB: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $22.00.